Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 310-319

  Mearns, Elizabeth S ^a,b   Kohn, Christine G ^a,b   Song, Ju Sung ^a   Hawthorne, Jessica ^a   Meng, Joy ^a   White, C Michael ^a,b   Raut, Monika K ^c   Schein, Jeff R ^c   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anticoagulation; International Normalized Ratio; Venous Thromboembolism; Vitamin K Antagonist

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; DICOUMAROL; PHENPROCOUMON; TECARFARIN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; BLEEDING; CORRELATION COEFFICIENT; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; EMBASE; EUROPE; HEALTH CARE QUALITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MEASUREMENT; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NORTH AMERICA; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG MONITORING; TREATMENT OUTCOME;

ANTICOAGULANTS; DRUG MONITORING; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84905112317     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.035     Document Type: Article

References (66)

1. S.Z. Goldhaber, and H. Bounameaux Pulmonary embolism and deep vein thrombosis Lancet 379 2012 1835 1846
2. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S e494S
3. P.M. Erkens, H. ten Cate, H.R. Büller, and M.H. Prins Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis PLoS ONE 7 2012 e42269
4. Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, and P. Glasziou et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
5. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
6. D.A. Cios, W.L. Baker, S.D. Sander, O.J. Phung, and C.I. Coleman Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis Am J Health Syst Pharm 66 2009 916 925
7. C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A.J. Forster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155 1166
8. S.J. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford, and M.G. Franzosi et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
9. G. Agnelli, P. Prandoni, M.G. Santamaria, P. Bagatella, A. Iorio, and M. Bazzan et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis N Engl J Med 345 2001 165 169
10. G. Agnelli, P. Prandoni, C. Becattini, M. Silingardi, M.R. Taliani, and M. Miccio et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism Ann Intern Med 139 2003 19 25
11. G. Agnelli, A. Gallus, S.Z. Goldhaber, S. Haas, M.V. Huisman, and R.D. Hull et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study Circulation 116 2007 180 187
12. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
13. C. Amiwero, I.A. Campbell, and R.J. Prescott A re-appraisal of warfarin control in the treatment of deep vein thrombosis and/or pulmonary embolism Afr Health Sci 9 2009 179 185
14. D. Aujesky, P.M. Roy, F. Verschuren, M. Righini, J. Osterwalder, and M. Egloff et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial Lancet 378 2011 41 48
15. R.D. Bona, A.D. Hickey, and D.M. Wallace Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis Am J Clin Oncol 23 2000 71 73
16. D.P. Brandjes, H. Heijboer, H.R. Büller, M. de Rijk, H. Jagt, and J.W. ten Cate Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N Engl J Med 327 1992 1485 1489
17. H.R. Büller, B.L. Davidson, H. Decousus, A. Gallus, M. Gent, and F. Piovella et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 2003 1695 1702
18. H.R. Buller, A.W. Lensing, M.H. Prins, G. Agnelli, A. Cohen, and A.S. Gallus et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study Blood 112 2008 2242 2247
19. H.R. Büller, A.S. Gallus, G. Pillion, M.H. Prins, and G.E. Raskob Cassiopea Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial Lancet 379 2012 123 129
20. A. Cafolla, R. Melizzi, E. Baldacci, P. Pignoloni, F. Dragoni, and M. Campanelli et al. "Zeus" a new oral anticoagulant therapy dosing algorithm: a cohort study Thromb Res 128 2011 325 330
21. R.S. Chitsike, M.A. Rodger, M.J. Kovacs, M.T. Betancourt, P.S. Wells, and D.R. Anderson et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study J Thromb Haemost 10 2012 2039 2044
22. The Columbus Investigators Low-molecular-weight heparin in the treatment of patients with venous thromboembolism N Engl J Med 337 1997 657 662
23. S.K. Das, A.T. Cohen, R.A. Edmondson, E. Melissari, and V.V. Kakkar Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial World J Surg 20 1996 521 526
24. M.E. Daskalopoulos, S.S. Daskalopoulou, E. Tzortzis, P. Sfiridis, A. Nikolaou, and D. Dimitroulis et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial Eur J Vasc Endovasc Surg 29 2005 638 650
25. J.D. Douketis, G.A. Foster, M.A. Crowther, M.H. Prins, and J.S. Ginsberg Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy Arch Intern Med 160 2000 3431 3436
26. Einstein Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
27. Einstein-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
28. R.S. Farraj Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J 25 2004 848 851
29. J.N. Fiessinger, M.V. Huisman, B.L. Davidson, H. Bounameaux, C.W. Francis, and H. Eriksson et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689
30. A.M. Gallagher, F. de Vries, J.M. Plumb, B. Haß, A. Clemens, and T.P. van Staa Quality of INR control and outcomes following venous thromboembolism Clin Appl Thromb Hemost 18 2012 370 378
31. J.A. Gonzalez-Fajardo, E. Arreba, J. Castrodeza, J.L. Perez, L. Fernandez, and I. Agundez et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis J Vasc Surg 30 1999 283 292
32. K.S. Heidinger, A. Bernardo, U. Taborski, and G. Müller-Berghaus Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis Thromb Res 98 2000 287 293
33. Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
34. B.A. Hutten, M.H. Prins, M. Gent, J. Ginsberg, J.G. Tijssen, and H.R. Büller Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 2000 3078 3083
35. C. Kearon, M. Gent, J. Hirsh, J. Weitz, M.J. Kovacs, and D.R. Anderson et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N Engl J Med 340 1999 901 907
36. C. Kearon, J.S. Ginsberg, M.J. Kovacs, D.R. Anderson, P. Wells, and J.A. Julian et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N Engl J Med 349 2003 631 639
37. C. Kearon, J.S. Ginsberg, D.R. Anderson, M.J. Kovacs, P. Wells, and J.A. Julian et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor J Thromb Haemost 2 2004 743 749
38. C. Kearon, J.S. Ginsberg, J.A. Julian, J. Douketis, S. Solymoss, and P. Ockelford et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism JAMA 296 2006 935 942
39. Y.K. Kim, R. Nieuwlaat, S.J. Connolly, S. Schulman, K. Meijer, and N. Raju et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study J Thromb Haemost 8 2010 101 106
40. M.M. Koopman, P. Prandoni, F. Piovella, P.A. Ockelford, D.P. Brandjes, and J. van der Meer et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group N Engl J Med 334 1996 682 687
41. M.N. Levine, J. Hirsh, M. Gent, A.G. Turpie, J. Weitz, and J. Ginsberg et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis Thromb Haemost 74 1995 606 611
42. P. López-Beret, A. Orgaz, J. Fontcuberta, M. Doblas, A. Martinez, and G. Lozano et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis J Vasc Surg 33 2001 77 90
43. A.K. Malik, and A.J. Taylor Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic South Med J 93 2000 58 61
44. M. Monreal, F.J. Roncales, J. Ruiz, J. Muchart, M. Fraile, and J. Costa et al. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin Haemostasis 28 1998 236 243
45. A.M. Njaastad, U. Abildgaard, and J.F. Lassen Gains and losses of warfarin therapy as performed in an anticoagulation clinic J Intern Med 259 2006 296 304
46. G. Palareti, C. Legnani, A. Lee, C. Manotti, J. Hirsh, and A. D'Angelo et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 2000 805 810
47. L.A. Pérez-de-Llano, V. Leiro-Fernández, R. Golpe, J.M. Núñez-Delgado, A. Palacios-Bartolomé, and L. Méndez-Marote et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study Blood Coagul Fibrinolysis 21 2010 744 749
48. Persist investigators A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation J Thromb Haemost 2 2004 47 53
49. M. Pini, S. Aiello, C. Manotti, C. Pattacini, R. Quintavalla, and T. Poli et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis Thromb Haemost 72 1994 191 197
50. L. Poller, M. Keown, S. Ibrahim, G. Lowe, M. Moia, and A.G. Turpie et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage J Thromb Haemost 6 2008 935 943
51. A. Romera, M.A. Cairols, R. Vila-Coll, X. Martí, E. Colomé, and A. Bonell et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis Eur J Vasc Endovasc Surg 37 2009 349 356
52. S. Schulman Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group J Intern Med 236 1994 143 152
53. S. Schulman, A.S. Rhedin, P. Lindmarker, A. Carlsson, G. Lärfars, and P. Nicol et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group N Engl J Med 332 1995 1661 1665
54. S. Schulman, S. Granqvist, M. Holmström, A. Carlsson, P. Lindmarker, and P. Nicol et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group N Engl J Med 336 1997 393 398
55. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
56. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
57. E.R. van Bladel, M.J. Agterof, B.D. Frijling, R. van der Griend, M.H. Prins, and R.E. Schutgens et al. Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect Thromb Res 126 2010 481 485
58. C.J. van Dongen, P. Prandoni, M. Frulla, A. Marchiori, M.H. Prins, and B.A. Hutten Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome J Thromb Haemost 3 2005 939 942
59. van Gogh Investigators Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 2007 1094 1104
60. M. Wieloch, A. Själander, V. Frykman, M. Rosenqvist, N. Eriksson, and P.J. Svensson Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 32 2011 2282 2289
61. V.J. Willey, M.F. Bullano, O. Hauch, M. Reynolds, G. Wygant, and L. Hoffman et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting Clin Ther 26 2004 1149 1159
62. N. Oake, D.A. Fergusson, A.J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis CMAJ 176 2007 1589 1594
63. B.L. Limone, A.V. Hernandez, D. Michalak, B.K. Bookhart, and C.I. Coleman Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials Thromb Res 132 2013 420 426
64. F. Laliberté, C.I. Coleman, B. Bookhart, P. Lefebvre, M. Cloutier, C.V. Damaraju, J.R. Schein, and S. Kaatz Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants Curr Med Res Opin May 2 2014 [Epub ahead of print]
65. J.D. Douketis, G.A. Foster, M.A. Crowther, M.H. Prins, and J.S. Ginsberg Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy Arch Intern Med 160 2000 3431 3436
66. E.A. Nutescu, S. Bathija, L.K. Sharp, B.S. Gerber, G.T. Schumock, and M.L. Fitzgibbon Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption Pharmacotherapy 31 2011 1161 1174